Yale Liver Center
New Haven, Connecticut, 06520, United States
NCT Number: NCT02950077
The study is a 'pilot study' to assess the effect of a mindfulness-based stress reduction (MBSR) intervention on patients with autoimmune liver disease specifically autoimmune hepatitis type I. MBSR is a standardized intervention that has shown benefit in addiction disorders and other psychiatric disorders. There has been no study evaluating or showing the benefit of the use of MBSR in autoimmune liver disease. With published data showing the evidence of an association of stress and relapse in autoimmune hepatitis, it is hypothesized that such an intervention such as MBSR may have therapeutic effect in patients with autoimmune liver disease.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
New Haven, Connecticut, 06520, United States
With the understanding that autoimmune hepatitis has a relationship with psychological stress, the use of a strategy such as mindfulness stress based reduction (MBSR) may similarly have a substantial impact as seen in other disease conditions. The proposed hypothesis is that undergoing MBSR has potential to benefit patients with autoimmune hepatitis in relation to decreased relapse rate and ultimately improved quality of life.
The focus of this study is surrounding the possibility of psychosocial stress for relapse in AIH. The investigators, however, would like to also understand the role of serological testing at the time of these relapses and during states of psychosocial stress to demonstrate if the association can be found. During active disease activity or relapses of autoimmune hepatitis, there is an expected rise in alanine aminotransferase (ALT) and immunoglobulin G (IgG) levels. Demonstrating the correlation of ALT and IgG with disease status and possible improvement with stress modifications is also key for this proposed study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Medical
Attitudinal
Physical
The intervention will be delivered in a group setting and the group will meet for 2 hours once per week for 8 weeks. The intervention is based on new neuroscience of stress and resilient adaptive behaviors, mindfulness based stress reduction, therapeutic breath and synchronized yogic movement with a focus on the lower abdomen, integrated with cognitive and behavioral strategies for self-control and healthy decision making.
Time frame: 12 months
Subjective Stress: The Perceived Stress Scale, a 14-item self-report scale that assesses the degree to which individuals appraise situations in their lives as stressful, will be used to assess subjective interpretation of stress and assign subjects to the low stress or high stress condition. Scale It has excellent test-retest reliability and good construct validity and has been used with adults and adolescents.
Scale ranges from 0 to 40. A higher score indicates higher stress.
Time frame: 12 months
The LES is a widely used 57 item self-report measure. It shows convergent validity with personality measures (e.g., anxiety) and is not correlated with social desirability measures.
Scale ranges from -250 to +250. A higher score indicates higher stress.
Time frame: 12 months
This self-report item measures how stressful subjects perceived situations occurring in the past year of their life.
Scale ranges from 0 to 351. A higher score indicates higher stress.
Time frame: 12 months
The Brief Self-Control Scale will be used to measure self-reported self-control and impulsivity. The BSCS also shows good internal consistency (alphas = .83 - .84) and high retest reliability (.87).
Scale ranges from 13-65. A higher score indicates better self-control.
Time frame: 12 months
Abnormal AST and ALT will be defined as >2x upper limits of normal
Normal Lab ranges that will be used are the following:
These levels are used together for clinical significance and diagnosis.
Time frame: 12 months
E.g (changes in monthly prednisone dose)
Time frame: up to 2 years
Relapse is defined in one of two ways once immunosuppression has been tapered off:
I. An increase in the AST or ALT ≥2 X ULN (upper limit of normal) II. An increase in AST and/or ALT ≥ 2 X the prior level of AST or ALT on routine labs checked at start of clinical study
Time frame: 12 months
Demonstration of a correlation of serum MIF and CD74 levels with autoimmune hepatitis disease activity.
Yale University
Other
Mindfulness - Based Stress Reduction and the Relationship on Inflammation in Autoimmune Hepatitis - A Human Pilot Study Protocol
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05532345
Autoimmune Diseases, Autoimmune Hepatitis
Beijing, China
View Trial DetailsNCT03217422
Autoimmune Diseases, Autoimmune Hepatitis
Coronado, California, United States
View Trial DetailsNCT05569759
Autoimmune Diseases, Autoimmune Hepatitis
Phoenix, Arizona, United States
View Trial DetailsNCT03743272
Autoimmune Diseases, Autoimmune Hepatitis
Leiden, Netherlands
View Trial Details